David Gray

David Gray

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2015 in Nature
Verified
Journal Article
Open access
PDF file
BBBeatriz Baragaña
Beatriz Baragaña
IHIrene Hallyburton
Irene Hallyburton
MLMarcus C. S. Lee
Marcus C. S. Lee
NNNeil R. Norcross
Neil R. Norcross
RGRaffaella Grimaldi
Raffaella Grimaldi
IGIan H. Gilbert
Ian H. Gilbert
There is an urgent need for new drugs to treat malaria, with broad therapeutic potential and novel modes of action, to widen the scope of treatment and to overcome emerging drug resistance. Here we describe the discovery of DDD107498, a compound with a potent and novel spectrum of antimalarial activity against multiple life-cycle stages of the Plasmodium parasite, with good pharmacokinetic properties and an acceptable safety profile. DDD107498 demonstrates potential to address a variety of clinical needs, including single-dose treatment, transmission blocking and chemoprotection. DDD107498 was developed from a screening programme against blood-stage malaria parasites; its molecular target has been identified as translation elongation factor 2 (eEF2), which is responsible for the GTP-dependent translocation of the ribosome along messenger RNA, and is essential for protein synthesis. This discovery of eEF2 as a viable antimalarial drug target opens up new possibilities for drug discovery.

1 April 2017 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
MFMark C. Field
Mark C. Field
DHDavid Horn
David Horn
AFAlan Fairlamb
Alan Fairlamb
MFMichael A. J. Ferguson
Michael A. J. Ferguson
DGDavid Gray
David Gray
IGIan H. Gilbert
Ian H. Gilbert

5 March 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IPImanol Peña
Imanol Peña
MMM. Pilar Manzano
M. Pilar Manzano
JCJuan Cantizani
Juan Cantizani
AKAlbane Kessler
Albane Kessler
JPJulio Alonso Padilla
Julio Alonso Padilla
JMJ. Julio Martin
J. Julio Martin
Using whole-cell phenotypic assays, the GlaxoSmithKline high-throughput screening (HTS) diversity set of 1.8 million compounds was screened against the three kinetoplastids most relevant to human disease, i.e. Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. Secondary confirmatory and orthogonal intracellular anti-parasiticidal assays were conducted and the potential for non-specific cytotoxicity determined. Hit compounds were chemically clustered and triaged for desirable physicochemical properties. The hypothetical biological target space covered by these diversity sets was investigated through bioinformatics methodologies. Consequently, three anti-kinetoplastid chemical boxes of ~200 compounds each were assembled. Functional analyses of these compounds suggest a wide array of potential modes of action against kinetoplastid kinases, proteases and cytochromes as well as potential host–pathogen targets. This is the first published parallel high throughput screening of a pharma compound collection against kinetoplastids. The compound sets are provided as an open resource for future lead discovery programs and to address important research questions.

8 April 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SWSusan Wyllie
Susan Wyllie
SBStephen Brand
Stephen Brand
MTMichael Thomas
Michael Thomas
MRManu De Rycker
Manu De Rycker
CCChun-Wa Chung
Chun-Wa Chung
PWPaul G. Wyatt
Paul G. Wyatt
Visceral leishmaniasis (VL), caused by the protozoan parasites Leishmania donovani and Leishmania infantum , is one of the major parasitic diseases worldwide. There is an urgent need for new drugs to treat VL, because current therapies are unfit for purpose in a resource-poor setting. Here, we describe the development of a preclinical drug candidate, GSK3494245/DDD01305143/compound 8, with potential to treat this neglected tropical disease. The compound series was discovered by repurposing hits from a screen against the related parasite Trypanosoma cruzi . Subsequent optimization of the chemical series resulted in the development of a potent cidal compound with activity against a range of clinically relevant L. donovani and L. infantum isolates. Compound 8 demonstrates promising pharmacokinetic properties and impressive in vivo efficacy in our mouse model of infection comparable with those of the current oral antileishmanial miltefosine. Detailed mode of action studies confirm that this compound acts principally by inhibition of the chymotrypsin-like activity catalyzed by the β5 subunit of the L. donovani proteasome. High-resolution cryo-EM structures of apo and compound 8-bound Leishmania tarentolae 20S proteasome reveal a previously undiscovered inhibitor site that lies between the β4 and β5 proteasome subunits. This induced pocket exploits β4 residues that are divergent between humans and kinetoplastid parasites and is consistent with all of our experimental and mutagenesis data. As a result of these comprehensive studies and due to a favorable developability and safety profile, compound 8 is being advanced toward human clinical trials.

1 July 2013 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MRManu De Rycker
Manu De Rycker
IHIrene Hallyburton
Irene Hallyburton
JTJohn Thomas
John Thomas
LCLorna Campbell
Lorna Campbell
SWSusan Wyllie
Susan Wyllie
DGDavid Gray
David Gray
Visceral leishmaniasis is a neglected tropical disease with significant health impact. The current treatments are poor, and there is an urgent need to develop new drugs. Primary screening assays used for drug discovery campaigns have typically used free-living forms of theLeishmaniaparasite to allow for high-throughput screening. Such screens do not necessarily reflect the physiological situation, as the disease-causing stage of the parasite resides inside human host cells. Assessing the drug sensitivity of intracellular parasites on scale has recently become feasible with the advent of high-content screening methods. We describe here a 384-well microscopy-based intramacrophageLeishmania donovaniassay and compare it to an axenic amastigote system. A panel of eight reference compounds was tested in both systems, as well as a human counterscreen cell line, and our findings show that for most clinically used compounds both axenic and intramacrophage assays report very similar results. A set of 15,659 diverse compounds was also screened using both systems. This resulted in the identification of seven new antileishmanial compounds and revealed a high false-positive rate for the axenic assay. We conclude that the intramacrophage assay is more suited as a primary hit-discovery platform than the current form of axenic assay, and we discuss how modifications to the axenic assay may render it more suitable for hit-discovery.

1 November 1992 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
DGDavid Gray
David Gray
IMIan Marshall
Ian Marshall
Isoprenaline (3 × 10−8−10−5m), salbutamol (3 × 10−7−10−4m) and forskolin (3 × 10−9−3 × 10−7m) relaxed rat isolated thoracic aortic rings contracted with noradrenaline (10−7m). Removal of the endothelium from the aortic rings abolished the effect of acetylcholine (10−6m) and completely prevented the vascular relaxation induced by isoprenaline, salbutamol or forskolin. The isoprenaline concentration‐relaxation curve was shifted in parallel to the right about 10 fold by propranolol (3 × 10−7m) with no change in the maximum response, showing that the relaxation was mediated by a β‐adrenoceptor. The inhibitor of nitric oxide synthesis, NG‐nitro‐l‐arginine (l‐NOARG; 10−5m), shifted the isoprenaline relaxation curve to the right and reduced the maximum response. Isoprenaline (10−6m) relaxed noradrenaline‐induced tone by approximately 95% and at the same time increased levels of adenosine 3′:5′‐cyclic monophosphate (cyclic AMP) 4 fold and guanosine 3′:5′‐cyclic monophosphate (cyclic GMP) 12 fold in the aortic rings. Sodium nitroprusside (3 × 10−8m) relaxed noradrenaline‐evoked tone by 82% without changing levels of cyclic AMP but raised cyclic GMP 19 fold. Forskolin (10−7m) relaxed noradrenaline‐induced tone by approximately 41% and, like isoprenaline, increased levels of cyclic AMP (2.5 fold) and cyclic GMP (12 fold) in the aortic rings. Removal of the endothelium abolished the relaxant effects of isoprenaline (10−6m) and also the associated accumulation of cyclic AMP and cyclic GMP. l‐NOARG (10−5m) inhibited the relaxant responses and accumulation of cyclic GMP induced by isoprenaline (10−6m) and forskolin (10−7m) without affecting the associated cyclic AMP accumulation. It is concluded that, in the rat aorta, isoprenaline acts through a β‐adrenoceptor on the endothelium to raise cyclic AMP and that this may, directly or indirectly, release nitric oxide to evoke vascular relaxation via the increase in cyclic GMP. The importance of this novel transduction pathway for cardiovascular regulation remains to be determined.